These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 27301277)

  • 1. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
    Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
    Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
    Marvin-Peek J; Jen WY; Kantarjian HM; McCue D; Haddad FG; Wierda W; Ferrajoli A; Burger J; Abusab T; Jorgensen J; Wang SA; Patel K; Loghavi S; O'Brien S; Ravandi F
    Leuk Lymphoma; 2024 Sep; 65(9):1325-1334. PubMed ID: 38749022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
    Ravandi F; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Koller C; Challagundla P; York S; Brandt M; Luthra R; Burger J; Thomas D; Keating M; Kantarjian H
    Blood; 2011 Oct; 118(14):3818-23. PubMed ID: 21821712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
    Kreitman RJ; Wilson W; Calvo KR; Arons E; Roth L; Sapolsky J; Zhou H; Raffeld M; Stetler-Stevenson M
    Clin Cancer Res; 2013 Dec; 19(24):6873-81. PubMed ID: 24277451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.
    Chihara D; Arons E; Stetler-Stevenson M; Yuan C; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James-Echenique L; Tai CH; Patel KP; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
    Blood Adv; 2021 Dec; 5(23):4807-4816. PubMed ID: 34607348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
    Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
    J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
    Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
    Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
    Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B
    N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine in hairy cell leukemia.
    Belani R; Saven A
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
    Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
    Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.
    Nieva J; Bethel K; Saven A
    Blood; 2003 Aug; 102(3):810-3. PubMed ID: 12663446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of patients with hairy cell leukemia in the south of Iran.
    Dehghani M; Kashkooe A; Namdari N; Majidi R; Karimi M; Haghighat S; Rezvani A; Safari N
    Expert Rev Hematol; 2023 Apr; 16(4):289-295. PubMed ID: 36709461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the treatment of the variant of hairy cell leukaemia: a case report.
    Hadzi-Pecova L; Stojanovik A; Petrusevska G; Panovska I
    Prilozi; 2008 Dec; 29(2):355-60. PubMed ID: 19259059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological management of hairy cell leukemia.
    Ramos Perez J; Ravandi-Kashani F
    Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant.
    Imamura T; Ohtsuka E; Ogata M; Oka F; Kashima K; Kikuchi H; Nasu M
    Int J Hematol; 2004 Dec; 80(5):432-4. PubMed ID: 15646655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hairy cell leukemia treated with cladribine].
    Ghanima W; Heldal D; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
    Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
    Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine.
    Sigal DS; Sharpe R; Burian C; Saven A
    Blood; 2010 Mar; 115(10):1893-6. PubMed ID: 20056789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
    Hoffman MA; Janson D; Rose E; Rai KR
    J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.